Telix Pharmaceuticals Limited (TLX)
NASDAQ: TLX · Real-Time Price · USD
9.85
+0.07 (0.72%)
At close: Dec 5, 2025, 4:00 PM EST
9.89
+0.04 (0.41%)
After-hours: Dec 5, 2025, 7:34 PM EST
Telix Pharmaceuticals Revenue
Telix Pharmaceuticals had revenue of $390.36M in the half year ending June 30, 2025, with 165.59% growth. This brings the company's revenue in the last twelve months to $664.23M, up 55.35% year-over-year. In the year 2024, Telix Pharmaceuticals had annual revenue of $484.69M with 41.49% growth.
Revenue (ttm)
$664.23M
Revenue Growth
+55.35%
P/S Ratio
5.01
Revenue / Employee
$1,570,273
Employees
423
Market Cap
3.33B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 484.69M | 142.12M | 41.49% |
| Dec 31, 2023 | 342.57M | 233.76M | 214.82% |
| Dec 31, 2022 | 108.81M | 103.29M | 1,870.12% |
| Dec 31, 2021 | 5.52M | 1.50M | 37.33% |
| Dec 31, 2020 | 4.02M | 1.57M | 64.26% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
TLX News
- 1 day ago - TLX LAWSUIT DEADLINE: Hagens Berman Urges Telix Investors to Act by Jan. 9 Over Alleged Dual Regulatory Failures: SEC Subpoena & FDA CRL on CMC/Supply Chain - PRNewsWire
- 2 days ago - Shareholders who lost money in shares of Telix Pharmaceuticals Ltd. (NASDAQ: TLX) Should Contact Wolf Haldenstein Immediately - GlobeNewsWire
- 2 days ago - INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals - GlobeNewsWire
- 4 days ago - Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability – Hagens Berman - GlobeNewsWire
- 4 days ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Telix Pharmaceuticals - Newsfile Corp
- 8 days ago - Telix Pharmaceuticals (TLX) Sued After Alleged Misstatements on Prostate Cancer Drug Progress and Supply Chain Reliability-- Hagens Berman - PRNewsWire
- 8 days ago - Bragar Eagel & Squire, P.C. Reminds Investors of Telix Pharmaceuticals and Firefly Aerospace to Contact the Firm About their Rights Before Lead Plaintiff Deadlines - GlobeNewsWire
- 12 days ago - The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of January 9, 2026 in Telix Pharmaceuticals Ltd. Lawsuit - TLX - PRNewsWire